drugset / Trial / NCT01372150
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
Timeline
- Start
- 2011-11-17
- Primary completion
- 2015-03-20
- Completion
- 2015-03-20
Outcome
Missed primary endpoint
registry analysis (superiority or other test); Placebo vs DVS SR; p = 0.739; Mean Difference (Final Values) -0.47 (95% CI -3.23 to 2.30); MMRM NCT01372150 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desvenlafaxine | Other / unclassified | 25 mg | Oral |
| Subject | Desvenlafaxine | Other / unclassified | 35 mg | Oral |
| Subject | Desvenlafaxine | Other / unclassified | 50 mg | Oral |
| Subject | Fluoxetine | Small molecule | 20 mg | Oral |